Cellular and T cell engager Immunotherapy
Efficacy/Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Yael C. Cohen, MD (she/her/hers)
Director of Myeloma Service
Tel- Aviv Sourasky (Ichilov) Medical Center, and Faculty of health Science, Tel Aviv University, Tel Aviv, Israel
Tel Aviv, Israel